Is nosocomial infection really the major cause of death in sepsis?

Neil M Goldenberg1, Aleksandra Leligdowicz2, Arthur S Slutsky2,3,4, Jan O Friedrich2,3 and Warren L Lee2,4*

Introduction
Over 25 clinical trials for sepsis have failed [1,2], suggesting that our current understanding of its pathogenesis is incomplete. Deaths occur days to weeks after diagnosis and have been attributed to one of two phenomena [3]. First, a subset of patients succumbs to an overwhelming acute inflammatory response driven by the innate immune system, leading to death within days of the initial infection. However, most patients survive this phase and the repeated failure of anti-inflammatory therapies for sepsis (for example, anti-tumor necrosis factor antibodies [4], high-dose corticosteroids [5]) indicates that inflammation per se is unlikely to be a major cause of death. Most sepsis deaths occur later and have been associated with dysfunction of the innate and adaptive immune systems [6], characterized by decreased cytokine production and lymphocyte apoptosis [7]. These mechanisms have been postulated to cause immunosuppression [3,8,9], predisposing patients to fatal nosocomial infections. Based on this hypothesis, immunoadjuvant therapy to boost the immune system has been proposed recently as a therapeutic approach.

The argument against nosocomial infection
The notion of death due to nosocomial infection is at odds with our clinical experience, in which patients with sepsis die despite broad-spectrum antibiotics and negative microbial cultures. Indeed, two studies often cited as evidence for this theory are open to alternative interpretations. The first study reported a high (~80 %) rate of infected foci in those patients dying from sepsis [10]. Yet it was unclear whether culture data reflected only postmortem or perimortem cultures, or incorporated laboratory results taken earlier during hospitalization—a period in which positive cultures would be expected.

The second study did not report the incidence of positive cultures in patients who died from sepsis, a critical statistic for determining the contribution of nosocomial infection to mortality [1]. This study described three phases of mortality, divided into deaths occurring within hospital days 0 to 5 (phase I), days 6 to 15 (phase II) and days 16 to 150 (phase III). Despite the fact that phase III included the largest number of days by far, the mortality rate was highest in phase I, arguing against late nosocomial infection being the main cause of death.

A recent retrospective analysis in our own center has provided further evidence against this theory. We considered all patients admitted to the ICU who were screened for a sepsis study of heparin (Heparin Anticoagulation to Improve Outcomes in Septic Shock; ClinicalTrials.gov NCT 1648036) and subsequently died. From these patients, we selected those who actually had sepsis and looked for evidence of a secondary nosocomial infection, defined as a detected new microbial isolate prior to death. Of 26 consecutive patients dying of septic shock in a mixed medical–surgical ICU, only three (14 %) patients had evidence of a new infection at the time of death (Table 1). While our study is not definitive, taken together with other results, the theory that nosocomial infection is the predominant cause of death from sepsis seems tenuous.

If not infection, what else?
Mitochondrial dysfunction
There is substantial evidence for mitochondrial dysfunction in sepsis [11]. The theory is that if perfusion and oxygen content are adequate but organ dysfunction still exists, the cells must be unable to use oxygen. Several factors, including reactive oxygen species, hormonal deficiencies, and the impact of systemic inflammation on mitochondrial gene transcription, are thought to contribute [11,12]. Furthermore, leukocytes from septic patients have been shown to possess abnormal oxygen metabolism [13], and mitochondrial dysfunction has been associated with poor outcomes in septic shock [14]. While trials of antioxidant...
| Age range (years) | Source of infection | SOFA score | ICU LOS (days) | Days from diagnosis to death | Days from final culture to death | Final culture result | Cause of death | Evidence of nosocomial infection |
|------------------|--------------------|------------|----------------|-----------------------------|---------------------------------|---------------------|---------------|-------------------------------|
| 70 to 79         | Lung               | 12         | 16             | 13                          | 1                               | No growth           | Cancer        | No nosocomial infection       |
| 60 to 69         | Skin and soft tissue | 9          | 55             | 55                          | 5                               | No growth           | CHF           | No nosocomial infection       |
| 80 to 89         | Genitourinary      | 12         | 1              | 14                          | 2                               | No growth           | CHF           | No nosocomial infection       |
| 70 to 79         | Bloodstream        | 15         | 17             | 17                          | 2                               | Original organism   | IE/sepsis     | No nosocomial infection       |
| 80 to 89         | Lung               | 18         | 54             | 73                          | <1                              | Original organism   | Ischemic bowel | No nosocomial infection       |
| 40 to 49         | Intra-abdominal    | 12         | 14             | 14                          | 14                              | No growth           | Liver failure  | No nosocomial infection       |
| 80 to 89         | Lung               | 11         | 12             | 10                          | 1                               | No growth           | MI            | No nosocomial infection       |
| 70 to 79         | Lung               | 10         | 5              | 3                           | 1                               | Original organism   | MI            | No nosocomial infection       |
| 40 to 49         | Bloodstream        | 21         | 14             | 4                           | 1                               | No growth           | MOF           | No nosocomial infection       |
| 50 to 59         | Bloodstream        | 15         | 16             | 33                          | 3                               | No growth           | MOF           | No nosocomial infection       |
| 40 to 49         | Intra-abdominal    | 17         | 4              | 5                           | 1                               | No growth           | MOF           | No nosocomial infection       |
| 70 to 79         | Intra-abdominal    | 16         | 42             | 43                          | 3                               | No growth           | MOF           | No nosocomial infection       |
| 60 to 69         | Lung               | 9          | 19             | 18                          | 2                               | No growth           | MOF           | No nosocomial infection       |
| 50 to 59         | Skin and soft tissue | 13         | 10             | 11                          | 1                               | No growth           | MOF           | No nosocomial infection       |
| 60 to 69         | Skin and soft tissue | 14         | 76             | 57                          | 2                               | No growth           | MOF           | No nosocomial infection       |
| <30              | Skin and soft tissue | 14         | 86             | 85                          | <1                              | No growth           | MOF           | No nosocomial infection       |
| 80 to 89         | Genitourinary      | 16         | 1              | 1                           | 1                               | Original organism   | MOF           | No nosocomial infection       |
| 70 to 79         | Lung               | 4          | 34             | 22                          | 3                               | No growth           | Tumor lysis    | No nosocomial infection       |
| 40 to 49         | Intra-abdominal    | 7          | 46             | 74                          | 1                               | New organism        | MOF           | Nosocomial infection          |
| 70 to 79         | Intra-abdominal    | 5          | 6              | 6                           | 1                               | New organism        | MOF           | Nosocomial infection          |
| <30              | Intra-abdominal    | 12         | 37             | 37                          | <1                              | New organism        | Pancreatitis    | Nosocomial infection          |
| 60 to 69         | Intra-abdominal    | 5          | 1              | 7                           | 3                               | New organism        | MOF           | Indeterminate                 |
| 50 to 59         | Skin and soft tissue | 12         | 37             | 37                          | 4                               | No growth           | MOF           | Indeterminate                 |
| 40 to 49         | Lung               | 16         | 68             | 50                          | 6                               | No growth           | MOF           | Indeterminate                 |
| 70 to 79         | Lung               | 13         | 17             | 17                          | 13                              | Original organism   | MOF           | Indeterminate                 |
| 70 to 79         | Intra-abdominal    | 14         | 3              | 13                          | <1                              | Original organism   | MOF           | Indeterminate                 |

The initial antibiotic therapy was checked against culture and sensitivity results to record the appropriateness of antibiotic therapy for the initial isolate. Results of the final culture before death and the time from that culture until death are indicated (<1 means the same day as death). CHF, congestive heart failure; IE, infective endocarditis; LOS, length of stay; MI, myocardial infarction; MOF, multiorgan failure; SOFA, Sequential Organ Failure Assessment.
therapy have been unsuccessful (reviewed in [2]), further trials are needed to determine the validity of this approach.

**Microvascular leak**
Another theory for death from sepsis implicates systemic vascular leak (Figure 1) [15,16]. Loss of endothelial barrier integrity leads to tissue edema, hypoperfusion, and organ dysfunction. These features are characteristic of human sepsis but until recently were absent from animal models. Importantly, various lines of evidence for this theory exist. In mice, buttressing the endothelial barrier directly protected against death from sepsis [17,18]. In humans, limiting fluids accelerated recovery in acute respiratory distress syndrome [19], while a positive fluid balance was associated with worse outcome in sepsis [20]; most recently, in a post hoc subgroup of the sickest sepsis patients, albumin therapy – which would limit edema formation – was also protective [21].

**Conclusion**
Sepsis has been termed a pharmaceutical ‘graveyard’ [22] due to repeated failure of human clinical trials. Despite calls for a trial of immunoadjuvant therapy, the evidence supporting nosocomial infection as the main cause of death is weak. A small study of granulocyte–macrophage colony-stimulating factor in patients with severe sepsis/
septic shock observed improvements in monocyte function but no significant change in a host of clinical parameters except for the duration of mechanical ventilation [23]. Practically, if most patients who die from sepsis have sterile cultures, it is unlikely that boosting the immune system or adding additional antibiotics will improve outcomes. Further research into the contribution of nosocomial infection to sepsis mortality is thus necessary, as well as research into other potential contributors such as systemic microvascular leak.

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
The retrospective chart review was approved by the Research Ethics Board at St Michael’s Hospital, Toronto, Ontario, Canada (REB 13-273c). The authors would like to thank the Heparin Anticoagulation to Improve Outcomes in Septic Shock research nurses and personnel for their help with this study.

Author details
1Keenan Research Centre for Biomedical Science, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1 W8, Canada.2Interdepartmental Division of Critical Care, University of Toronto, 30 Bond Street, Bond Wing 4-012, Toronto, Ontario M5B 1 W8, Canada.3Li Ka Shing Knowledge Institute, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1 W8, Canada.4Keenan Research Centre for Biomedical Science, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1 W8, Canada.5Centre for Biomedical Science, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1 W8, Canada.6Humber River Regional Hospital, North York, Ontario, Canada (#REB 13-273c). The authors would like to thank the Heparin Anticoagulation to Improve Outcomes in Septic Shock research nurses and personnel for their help with this study.

Published online: 01 October 2014

References
1. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Bauer M, Reinhart K, Sossdorf M, Rödel J, Menge K, Reinhart K, Bauer M, Riederer G, Payen D: Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007, 35:2702–2708.
2. Riedemann NC, Guo R-F, Ward PA: A novel take on sepsis pathogenesis. Sci Transl Med 2011, 3:88ps25.
3. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. The Lancet 2002, 360:219–223.
4. Lee WL, Slutsky AS: Sepsis and endothelial permeability. N Engl J Med 2010, 363:689–691.
5. Goldenberg NW, Steinberg BE, Slutsky AS, Lee WL: Broken barriers: a new take on sepsis pathogenesis. Crit Care Med 2011, 39:1831–1839.
6. Kumpers P, Gueter F, David S, Slyke PV, Dumont DJ, Park J-K, Bockmeyer CL, Parikh SM, Ravenstaid H, Hallet H, Shushakova N: The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 2011, 15:R261.
7. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. The Lancet 2002, 360:219–223.
8. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Bauer M, Riederer G, Payen D: Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007, 35:2702–2708.
9. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260–268.
10. Jindal M, Thaete FL, Leitner H, Tümer M, Tümer CR, Tripkovic L, Shapira Y, Payen D, Monneret G: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:653–658.
11. Goel RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:653–658.
12. Singer M: Powering up failed organs. Am J Respir Crit Care Med 2007, 176:733–734.
13. Belikova I, Lukaszewicz AC, Fairev V, Damoisel C, Singer M, Payen D: Oxygen consumption of human peripheral blood mononuclear cells in severe human sepsis. Crit Care Med 2007, 35:2702–2708.
14. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. The Lancet 2002, 360:219–223.
15. Lee WL, Slutsky AS: Sepsis and endothelial permeability. N Engl J Med 2010, 363:689–691.
16. Goldenberg NW, Steinberg BE, Slutsky AS, Lee WL: Broken barriers: a new take on sepsis pathogenesis. Crit Care Med 2011, 39:1831–1839.
17. Kumpers P, Gueter F, David S, Slyke PV, Dumont DJ, Park J-K, Bockmeyer CL, Parikh SM, Ravenstaid H, Hallet H, Shushakova N: The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 2011, 15:R261.
18. Heart N, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, DeBoer BL, Connors AF, Hite RD, Harabin AL: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354:2564–2575.
19. Kumpers P, Gueter F, David S, Slyke PV, Dumont DJ, Park J-K, Bockmeyer CL, Parikh SM, Ravenstaid H, Hallet H, Shushakova N: The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 2011, 15:R261.
20. Boyd JH, Forbes J, Nakada T-A, Walley KR, Russell JA: Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011, 39:259–265.
21. Caroni P, Tognoni G, Mason S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Pariro V, Fiore G, Lati R, Gattinoni L, ALBIOS Study Investigators: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2011, 364:371–384.
22. Reddemann NC, Guo R-F, Ward PA: The enigma of sepsis. J Clin Invest 2003, 112:460–467.
23. Meisel C, Schefold JC, Pischowks R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hauser D, Keh D, Zuckermann H, Reinke P, Volk H-D: Granulocyte–macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:540–548.

doi:10.1186/s13054-014-0540-y
Cite this article as: Goldenberg et al.: Is nosocomial infection really the major cause of death in sepsis? Critical Care 2014 18:540.